Nalaganje...
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
BACKGROUND: Raltegravir is an integrase inhibitor approved for use in adults and children with HIV-1 infection, but there are no data on the long-term use of this medication in children. We aimed to assess the long-term safety, tolerability, pharmacokinetics, and efficacy of multiple raltegravir for...
Shranjeno v:
| izdano v: | Lancet HIV |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6537590/ https://ncbi.nlm.nih.gov/pubmed/30527329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(18)30257-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|